AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
ICER said AstraZeneca’s newly approved hypertension drug Baxfendy (baxdrostat) fails its cost-effectiveness bar versus price. In a draft report, ICER used a $900 WAC for 30 tablets, implying $10,800 annual cost pre-discounts. ICER also assessed lorundrostat and found similar results, citing inconclusive comparative benefits and questions on long-term ASI effects.
How this was made
The 30-second read
Why it matters
ICER concludes Baxfendy is too expensive versus effectiveness under traditional cost-effectiveness thresholds, using a $900 WAC for 30 tablets and an annualized $10,800 cost. It also flags unresolved long-term effects of ASIs and subgroup efficacy/safety questions, particularly in chronic kidney disease. While not a regulatory denial, the assessment can influence payer and formulary discussions and increase perceived reimbursement risk for AZN’s commercialization plan.
Market read
Traders should monitor payer/HTA sentiment around Baxfendy, since ICER’s draft frames the drug as not meeting value thresholds at list price and highlights long-term uncertainty.
What to watch
The report is draft and acknowledges limitations in comparing trials; payer decisions may hinge on longer-term outcomes and real-world BP reduction durability, especially in CKD subgroups.
Background
AstraZeneca’s first-in-class hypertension drug Baxfendy (baxdrostat) was FDA-approved in May and is positioned for use with other antihypertensives in patients whose BP is not adequately controlled.
Ticker impact
ICER’s draft report says AstraZeneca’s Baxfendy fails cost-effectiveness at a $900 WAC, using an annualized $10,800 cost.
Moderate downside bias for AZN until reimbursement/coverage details clarify.
The article is a draft ICER assessment, not an FDA action, but it directly targets price-to-value and highlights unresolved long-term efficacy/safety questions, which can influence formulary decisions.
Market effects
Reinforces scrutiny on high-priced hypertension drugs and ASI-class value claims, potentially weighing on similar late-stage launches.
Primarily US payer and HTA dynamics, with spillover to global pricing expectations for AZN’s portfolio.
Could affect international pricing negotiations if US HTA skepticism becomes a template for other markets.
Counterpoint
ICER uses WAC and cross-trial placeholders; real-world net pricing after rebates and any subgroup benefits could still support coverage.
Key entities
- companyAstraZeneca
Subject of the article via its newly approved hypertension drug Baxfendy and its commercialization outlook.
- drugBaxfendy
AstraZeneca’s first-in-class hypertension drug assessed by ICER for cost-effectiveness.
- organizationInstitute for Clinical and Economic Review (ICER)
US drug price watchdog issuing a draft cost-effectiveness report.
- companyCinCor Pharma
Developer of Baxfendy, acquired by AstraZeneca in a $1.3 billion buyout in 2023.
- companyMineralys Therapeutics
Company with investigational lorundrostat assessed by ICER using the same placeholder pricing approach.
